Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Trastuzumab biosimilar - Sunshine Guojian Pharmaceutical

Next Previous
Drug Profile

Trastuzumab biosimilar - Sunshine Guojian Pharmaceutical

Alternative Names: 302 - 3SBio; 302H - 3SBio; Cipterbin; CMAB 302; Inetetamab

Latest Information Update: 09 Feb 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Shanghai CP Guojian Pharmaceutical
  • Developer Sunshine Guojian Pharmaceutical
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; ERBB 2 receptor antagonists; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Breast cancer

Most Recent Events

  • 06 Dec 2022 Efficacy and adverse events data from a phase II trial in Breast cancer presented at the 45th Annual San Antonio Breast Cancer Symposium (SABCS-2022)
  • 25 Jun 2021 Sun Yat-Sen University initiates the phase II Increase trial for Breast cancer (Combination therapy, Metastatic disease, Second-line therapy or greater) in China (IV) (NCT04941885)
  • 03 Feb 2021 Peking Union Medical College plans a phase III trial for Breast cancer (Combination therapy, Metastatic disease, Second-line therapy or greater) in China (IV) in February 2021 (NCT04736589)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top